« Back Record Document

Access to medicines and incentives for innovation: The balance struck in the Trans-Pacific Partnership (TPP) on intellectual property (patent and data exclusivity) protection for pharmaceutical products

2016-11

LC/L.4248
LC/WAS/L.143

This study addresses the balance struck under the Trans-Pacific Partnership Agreement (TPPA) between the right to health and access to medicines and the need to maintain the economic incentives to spur innovation and research and development through intellectual property protection. The analysis focuses on the patent and data-related intellectual property protection provisions of the TPPA, specifically regarding pharmaceutical (small-molecule and biologic) products, including on patent duration, linkage and term extensions as well as clinical test data protection and market exclusivity. Special attention is paid to the United States and its negotiating position with respect to those aspects of intellectual property rights, as it has been and remains the world’s principal demandeur for high intellectual property rights (IPR) standards in trade agreements, including the TPPA.

Abstract .-- Introduction .-- I. Key trends in the global, regional and U.S. pharmaceutical industries .-- II. Patent and regulatory data-related protection on pharmaceutical products in TPP .-- III. Congressional mandates on intellectual property protection on pharmaceutical products .-- IV. Conclusions.

Comisión Económica para América Latina y el Caribe (CEPAL) - Biblioteca Hernán Santa Cruz

Héctor Aracena

Biblioteca CEPAL, Edificio Naciones Unidas, Av. Dag Hammarskjold 3477, Santiago, Chile

(+56-2) 2210-2337


Address: Av. Mariscal Antonio José de Sucre N58-63 y Fernández Salvador Edif. Olade - San Carlos, Quito - Ecuador.

Web: www.olade.org

Phone: (593 2) 259 8122 / 2598 280

Correo: realc@olade.org

ADMIN
Desarrollado por: Aikyu-Systems